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letter to editorPlerixafor in the treatment
of progenitor cell
mobilization failure: First
experience in AlgeriaTo the Editor: Autologous pro-
genitor cell transplantation
(APCT) after a high dose of con-
ditioning chemotherapy is now an
established treatment modality for
many hematological malignancies.
Clinical results and survival after
APCT depend on disease chemo-
sensitivity at transplant, efﬁcacy
of the conditioning regimen, and
quantity of CD34+ cells infused.1
Most autologous progenitor cell
mobilization protocols use either a
combination of chemotherapy and
a growth factor,2 or a growth
factor alone.3 Mobilization failure
in patients is a major therapeutic
concern which makes subsequent
APCT impossible. A new growth
factor called plerixafor,4 developed
by the pharmaceutical industry, is
especially indicated for mobiliza-
tion failure.Table 1. Patient characteristics.
N patient Age Gender
1 49 F
2 59 M
3 26 F
4 52 F
5 60 F
6 56 F
7 50 F
8 24 F
9 28 F
10 33 F
11 46 F
12 27 M
13 43 M
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ﬁrst experience of the use of pler-
ixafor for CD34+ mobilization in
Algeria.
A total of 221 autografts were
performed at our center from
May 2009–31 July 2014. The
main indications for autograft
were multiple myeloma (MM)
(148 patients), Hodgkin’s lym-
phoma (HL) (60 patients), and
non-Hodgkin’s lymphoma
(NHL) (13 patients). The mobi-
lization protocol involved subcu-
taneous G-CSF (ﬁlgrastim)
alone at the dose of 15 lg/kg
body weight/day for ﬁve days.
Mobilization failure is declared
when the number of CD34+ is
less than 2.106/kg body weight.
Thirteen patients did not mobi-
lize CD34+. With patients expe-
riencing mobilization failure, we
used plerixafor at 0.24 mg/kg
body weight combined with G-
CSF. Harvesting took place six
to ten hours after plerixafor
injection.Diagnosis Line treatment Num
NHL R-CHOP/DHAP/ICE
NHL R-CHOP/R-DHAP/ICE
NHL CHOP/DHAP/ESHAP
MM VAD/CTD/VCD
MM VAD/VCD/VTD
MM CTD/VCD
NHL CHOP/DHAP/ESHAP
HL ABVD/DHAP
HL ABVD/BEACOPP/DHAP
HL ABVD/BEACOPP/DHAP
HL ABVD/BEACOPP/ESHAP
HL ABVD/BEACOPP/ESHAP
HL ABVD/DHAP/ESHAP
015Table 1 shows the clinical char-
acteristics of the 13 patients, who
had a median age of 46 years
(24–64), were predominantly
female (10 W/3 M) and had a
median of three treatment lines.
Ten patients received a single pler-
ixafor injection, and three patients
received one injection per day for
two days. Mean CD34+ count
with G-CSF alone was
0.76 · 106/kg, and with plerixafor
was 3.26 · 106/kg (p = 0.014).
Among the 13 patients who
received plerixafor, nine patients
received intensiﬁcation with
APCT, with a median CD34+
concentration of 2.34 · 106/kg.
Engraftment was complete in these
nine patients over a 13-day
engraftment period. Four patients
did not mobilize with plerixafor.
Mobilization failure during
APCT is a major concern in the
therapeutic management of
patients with hematological malig-
nancies. In our series of 13
patients, mobilization failure withber of apheresis Mobilization results
3 Successful
2 Successful
3 Failed
3 Failed
2 Successful
2 Successful
2 Successful
3 Successful
2 Successful
2 Failed
3 Successful
2 Failed
3 Successful
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plerixafor affected patients with
lymphoma (n = 3) and one patient
with MM on a multiple therapy
regimen.
Plerixafor enabled us to
increase CD34+ count four fold
and to salvage almost 70% of cases
of primary mobilization failure
with a single injection for most
patients (n = 8) and two injections
for one patient.
In conclusion, our experience in
the use of plerixafor enabled us to
show effectiveness in autologous
progenitor cell mobilization with
a salvage rate of almost 70%.CONFLICT OF INTEREST
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